Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy

Update on Immune Checkpoint Inhibitors in Lung Cancer

(2017) Benjamin C. Creelan   Cancer Control

Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities

(2013) Barbara Merelli et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

(2013) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

(2013) Charles G. Drake et al.   Nature Reviews Clinical Oncology

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Newer developments in the immunotherapy of malignant melanoma

(2013) Benjamin Maslin et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

(2012) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting PD-1/PD-L1 interactions for cancer immunotherapy

(2012) Laurence Zitvogel et al.   OncoImmunology

Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

(2011) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

(2010) Frank R. Brennan et al.   mAbs

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy

(2010) Axel Hoos et al.   SEMINARS IN ONCOLOGY

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

(2009) Celestia S. Higano et al.   CANCER

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

(2009) Jedd D Wolchok et al.   LANCET ONCOLOGY

Outbreak of Pneumocystis jiroveci Pneumonia in Renal Transplant Recipients: P. jiroveci Is Contagious to the Susceptible Host

(2009) Hirohisa Yazaki et al.   TRANSPLANTATION

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH

The calm after the cytokine storm: lessons from the TGN1412 trial

(2008) E. William St. Clair   JOURNAL OF CLINICAL INVESTIGATION

Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review

(2008) Bertrand Coiffier et al.   JOURNAL OF CLINICAL ONCOLOGY